Research Grade
Reaktivität: Human
ELISA, WB
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
Applikationshinweise
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by Infliximab.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Konservierungsmittel
Without preservative
Handhabung
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.
Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.